Table 2.

Characteristics of included studies that assessed the risk of hepatocellular carcinoma recurrence*

Ref.	First author	Year	City	Country	Study period	Design	N	Therapy	T2DM	N events	No T2DM	N events
18	Poon	2002	Hong Kong	China	Jan 1989-Sep 1999	Retro	525	HR	62	35	463	275
20	Huo	2004	Taipei	Taiwan	Apr 1996-March 2001	Retro	255	HR	41	18	214	104
21	Komura	2007	Ishikawa	Japan	Jun 1987-May 2004	Retro	90	HR	30	22	60	27
23	Kawamura	2008	Tokyo	Japan	Jan 1980-Dec 2006	Retro	40	HR/RFA	18	15	22	7
26	Chen	2011	Taichung	Taiwan	Jul 2003-Jun 2009	Retro	53	RFA	53	30	82	19
27	Howell	2011	Melbourne	Australia	Jan 2000-Aug 2007	Retro	135	Mix	58	17	77	19
29	Ting	2012	Taipei	Taiwan	Jan 2000-Dec 2008	Retro	389	HR	117	63	272	116
30	Hosokawa	2013	Tokyo	Japan	Jan 1999-Dec 2007	Retro	344	RFA	159	116	185	138
34	Wang	2014	Nanning	China	Jun 2003-Feb 2011	Retro	505	HR	134	57	371	175
36	Chan	2016	Taipei	Taiwan	Jan 1995-Dec 2011	Retro	26 267	HR	6663	2851	19 604	8380
38	Choi	2017	Busan	Korea	Jan 2010-Sep 2014	Retro	58	HR	14	8	44	12
39	Yoshida	2017	Tokyo	Japan	Jan 2001-Dec 2013	Retro	224	HR	112	69	112	74
40	Li	2018	Hangzhou	China	Jan 2008-Dec 2015	Retro	11 048	LT	3136	282	7912	489
42	Billeter	2020	Heidelberg	Germany	Oct 2001-Dec 2017	Retro	88	HR	44	26	44	25
Total	-	-	-	-	-	-	40 021	-	10 641	3609	29 462	9860

*Abbreviations: Ref – reference; N – number; T2DM – type 2 diabetes mellitus; retro – retrospective; HR – hepatic resection; RFA – radiofrequency ablation; LT – liver transplantation.